DE69327456T2 - VERFAHREN ZUR ELIMINIERUNG VON INHIBIERENDEN/DESTABILISIERENDEN REGIONEN VON mRNA - Google Patents

VERFAHREN ZUR ELIMINIERUNG VON INHIBIERENDEN/DESTABILISIERENDEN REGIONEN VON mRNA

Info

Publication number
DE69327456T2
DE69327456T2 DE69327456T DE69327456T DE69327456T2 DE 69327456 T2 DE69327456 T2 DE 69327456T2 DE 69327456 T DE69327456 T DE 69327456T DE 69327456 T DE69327456 T DE 69327456T DE 69327456 T2 DE69327456 T2 DE 69327456T2
Authority
DE
Germany
Prior art keywords
destabilizing
mrna
inhibiting
eliminating
regions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69327456T
Other languages
English (en)
Other versions
DE69327456D1 (de
Inventor
George Pavlakis
Barbara Felber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69327456D1 publication Critical patent/DE69327456D1/de
Publication of DE69327456T2 publication Critical patent/DE69327456T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69327456T 1992-03-27 1993-03-29 VERFAHREN ZUR ELIMINIERUNG VON INHIBIERENDEN/DESTABILISIERENDEN REGIONEN VON mRNA Expired - Lifetime DE69327456T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/858,747 US6174666B1 (en) 1992-03-27 1992-03-27 Method of eliminating inhibitory/instability regions from mRNA
PCT/US1993/002908 WO1993020212A1 (en) 1992-03-27 1993-03-29 METHOD OF ELIMINATING INHIBITORY/INSTABILITY REGIONS OF mRNA

Publications (2)

Publication Number Publication Date
DE69327456D1 DE69327456D1 (de) 2000-02-03
DE69327456T2 true DE69327456T2 (de) 2000-08-10

Family

ID=25329086

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69327456T Expired - Lifetime DE69327456T2 (de) 1992-03-27 1993-03-29 VERFAHREN ZUR ELIMINIERUNG VON INHIBIERENDEN/DESTABILISIERENDEN REGIONEN VON mRNA

Country Status (7)

Country Link
US (6) US6174666B1 (de)
EP (1) EP0635062B1 (de)
JP (4) JP4180650B2 (de)
AU (1) AU678157B2 (de)
CA (1) CA2132208C (de)
DE (1) DE69327456T2 (de)
WO (1) WO1993020212A1 (de)

Families Citing this family (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3765103B2 (ja) * 1992-02-28 2006-04-12 シンジェニックス・リミテッド Ｍｐｍｖ及びｈｉｖに基づく欠損パッケージング非オンコウイルスベクター
US6174666B1 (en) * 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
AU709401B2 (en) * 1994-08-30 1999-08-26 Austin Research Institute, The Improvements in production of proteins in host cells
AUPM772494A0 (en) * 1994-08-30 1994-09-22 Austin Research Institute, The Improvements in production of proteins in host cells
DE69737597D1 (de) * 1996-07-22 2007-05-24 Us Gov Health & Human Serv Vektoren zur inhibierung von viralem und tumorwachstum
EP0953647B1 (de) * 1996-12-16 2008-05-28 Eisai R&D Management Co., Ltd. Verfahren zur herstellung von retroviralen vektoren für die gentherapie
WO1999019501A1 (en) * 1997-10-14 1999-04-22 Institute For Vaccine Development Non-integrating dna vector of retroviral origin having high-protein expression, and secreted immunogenic antigens
US7598079B2 (en) * 1998-12-24 2009-10-06 Novation Pharmaceuticals, Inc. Assay for identifying compounds which affect stability of mRNA
GB9828709D0 (en) * 1998-12-24 1999-02-17 Novartis Ag Assay
EP1980617A1 (de) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Verbesserte Expression von HIV-Polypeptiden und Herstellung virusähnlicher Partikel
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
JP4776075B2 (ja) * 1998-12-31 2011-09-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改変ｈｉｖｅｎｖポリペプチド
JP2003523721A (ja) * 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
US6656706B2 (en) * 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
AU785133B2 (en) * 1999-12-23 2006-10-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Molecular clones with mutated HIV GAG/POL, SIV GAG and SIV ENV genes
US6582920B2 (en) * 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
DE60040874D1 (de) * 2000-09-01 2009-01-02 Gen Probe Inc Amplifizierung von hiv-1 sequenzen zur detektion ven einhergehen
CA2424216A1 (en) 2000-10-04 2002-04-11 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
JP2002125687A (ja) * 2000-10-30 2002-05-08 Tosoh Corp Ｈｉｖ−１検出のためのオリゴヌクレオチドおよび検出法
WO2002036806A2 (en) * 2000-11-01 2002-05-10 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Expression vectors able to elicit improved immune response and methods of using same
JP4701532B2 (ja) * 2001-04-26 2011-06-15 東ソー株式会社 Ｈｉｖ−１ｒｎａの増幅および検出法
EP2305699B1 (de) * 2001-06-05 2014-08-13 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose
US7205278B2 (en) 2001-06-14 2007-04-17 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
BR0210586A (pt) * 2001-06-22 2005-07-12 Wistar Inst Métodos para induzir uma reação imune citotóxica e composições de adenovìrus de sìmio recombinante úteis das mesmas
WO2003004620A2 (en) * 2001-07-05 2003-01-16 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2452119C (en) * 2001-07-05 2013-10-15 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
AU2002316578A1 (en) * 2001-08-31 2003-03-18 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
US6835568B2 (en) * 2001-10-30 2004-12-28 Virxsys Corporation Regulated nucleic acid expression system
CA2406745C (en) 2001-11-13 2006-01-10 The Trustees Of The University Of Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
EP1944043A1 (de) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Nukleinsäure- und Aminosäuresequenzen von Affen-Adenoviren, hergeleitete Vektoren und Verwendungsverfahren.
HU230364B1 (hu) 2001-11-21 2016-03-29 The Trustees Of The University Of Pennsylvania Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására
DE10162480A1 (de) * 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
US7943146B2 (en) * 2001-12-21 2011-05-17 Myrexis, Inc. Immunizing compositions comprising HIV-1 proviral constructs with an inactive p6 gag TSG101 UEV binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface
US20050075298A1 (en) * 2002-01-31 2005-04-07 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa
US20040043003A1 (en) * 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
US20040009937A1 (en) * 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
US6974762B2 (en) * 2002-08-01 2005-12-13 Intel Corporation Adhesion of carbon doped oxides by silanization
AU2002953015A0 (en) * 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
CN1301263C (zh) * 2002-12-18 2007-02-21 北京昭衍新药研究中心 一组抗hiv感染及防治艾滋病的核苷酸序列及其应用
DE60333035D1 (de) * 2002-12-23 2010-07-29 Vical Inc Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US8426194B2 (en) 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
EP1604011A4 (de) 2003-01-21 2009-12-09 Ptc Therapeutics Inc Verfahren zur identifizierung von verbindungen, die die von nichttranslatierten bereichen abhängige genexpression modulieren, sowie verfahren zur verwendung davon
AU2005250477A1 (en) * 2004-06-04 2005-12-15 Wyeth Enhancing protein expression
CA2891079A1 (en) 2004-06-07 2005-12-22 Jeffrey A. Johnson Real-time pcr point mutation assays for detecting hiv-1 resistance to antiviral drugs
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
EP2357010B1 (de) 2005-04-07 2013-06-12 The Trustees of The University of Pennsylvania Verfahren zur Erhöhung der Funktion eines AAV-Vektors
PL3263581T3 (pl) 2005-05-17 2021-05-04 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
CN102796743B (zh) 2006-01-13 2015-11-18 美国政府健康及人类服务部国立卫生研究院 用于在哺乳动物细胞中表达的密码子优化的IL-15和IL-15Rα基因
EP2468297B1 (de) * 2006-07-13 2015-09-02 Institute For Advanced Study Methoden zur identifizierung von Angenzien, die das AGG-Motif binden
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
WO2009002562A2 (en) 2007-06-27 2008-12-31 Marine Polymer Technologies, Inc. Complexes of il-15 and il-15ralpha and uses thereof
MX2010005860A (es) 2007-11-28 2010-06-22 Univ Pennsylvania Adenovirus simianos de la subfamilia c sadv-40, sadv-31 y sadv-34 y usos de los mismos.
PL2220241T3 (pl) 2007-11-28 2017-06-30 The Trustees Of The University Of Pennsylvania Adenowirus zawierający kapsydowe białko heksonu SAdV-39 małpiego adenowirusa E oraz jego zastosowanie
WO2009136977A2 (en) 2008-03-04 2009-11-12 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
US8715964B2 (en) 2008-05-11 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Expression of IL-12 family heterodimers
US8126653B2 (en) * 2008-07-31 2012-02-28 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
US7561973B1 (en) 2008-07-31 2009-07-14 Dna Twopointo, Inc. Methods for determining properties that affect an expression property value of polynucleotides in an expression system
US8401798B2 (en) * 2008-06-06 2013-03-19 Dna Twopointo, Inc. Systems and methods for constructing frequency lookup tables for expression systems
US7561972B1 (en) 2008-06-06 2009-07-14 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
JP5809978B2 (ja) 2008-10-31 2015-11-11 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア サルアデノウイルスＳＡｄＶ−４３、−４５、−４６、−４７、−４８、−４９および−５０ならびにそれらの用途
EP2435559A1 (de) 2009-05-29 2012-04-04 The Trustees Of The University Of Pennsylvania Affen-adenovirus 41 und verwendungen davon
WO2011106705A2 (en) 2010-02-26 2011-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Dna-protein vaccination protocols
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
LT3590949T (lt) 2010-10-01 2022-07-25 Modernatx, Inc. Ribonukleorūgštys, kurių sudėtyje yra n1-metil-pseudouracilų, ir jų naudojimas
EP2625577B1 (de) 2010-10-08 2019-06-26 Terumo BCT, Inc. Anpassbares verfahren und systeme für züchtung und ernte von zellen in einem hohlfaser-bioreaktorsystem
WO2012071318A2 (en) 2010-11-23 2012-05-31 The Trustees Of The University Of Pennsylvania Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
EP2691530B1 (de) 2011-06-10 2018-03-07 Oregon Health & Science University Cmv-glycoproteine und rekombinante vektoren
SG10201604767TA (en) 2011-06-13 2016-08-30 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies and uses thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
MX354267B (es) 2011-10-03 2018-02-21 Moderna Therapeutics Inc Star Nucléosidos, nucleótidos, y ácidos nucleicos modificados, y usos de los mismos.
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
EP2620446A1 (de) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogene zur HIV-Impfung
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2868996A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
MX358019B (es) 2012-05-18 2018-08-02 Univ Pennsylvania Adenovirus de simio de la subfamilia e a1302, a1320, a1331 y a1337 y sus usos.
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
RU2681730C2 (ru) 2012-07-25 2019-03-12 Селлдекс Терапьютикс Инк. Антитела против kit и их применения
CA2888896A1 (en) 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
EP3052106A4 (de) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynukleotide zur codierung immunmodulierender polypeptide
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
EP3068866B1 (de) 2013-11-16 2018-04-25 Terumo BCT, Inc. Zellenexpansion in einem bioreaktor
EP3613841B1 (de) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passives ersetzen von medien
JP6974943B2 (ja) 2014-05-13 2021-12-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ２種の抗体構築物を発現するａａｖを含む組成物およびこの使用
MA47849A (fr) 2014-05-28 2020-01-29 Agenus Inc Anticorps anti-gitr et leurs procédés d'utilisation
ES2811974T3 (es) 2014-07-29 2021-03-15 Novartis Ag Regímenes de aumento escalonado de la dosis del heterodímero de il-15 e il-15ralfa para tratar afecciones
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
MX2017014188A (es) 2015-05-07 2018-04-10 Agenus Inc Anticuerpos anti-ox40 y metodos para su uso.
EP4276106A3 (de) 2015-05-13 2024-01-24 The United States of America as represented by the Secretary of the Department of Health and Human Services Methoden und zusammensetzungen beruhend auf konstruktenenthaltend konservierte elemente zur induktion einer immunantwort
KR102492532B1 (ko) 2015-05-29 2023-01-30 아게누스 인코포레이티드 항-ctla-4 항체 및 이의 사용 방법
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3344656A1 (de) 2015-09-01 2018-07-11 Agenus Inc. Anti-pd-1-antikörper und verfahren zur verwendung davon
CN108603200B (zh) * 2015-11-23 2022-08-19 诺华股份有限公司 优化的慢病毒转移载体及其用途
US10472422B2 (en) 2016-01-08 2019-11-12 Abgenomics International Inc. Tetravalent anti-PSGL-1 antibodies and uses thereof
JP7140683B2 (ja) 2016-04-15 2022-09-21 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規なａａｖ８変異カプシド及びそれを含有する組成物
CN109415696A (zh) 2016-05-25 2019-03-01 泰尔茂比司特公司 细胞扩增
MY195089A (en) 2016-05-27 2023-01-10 Agenus Inc Anti-Tim-3 Antibodies and Methods of use thereof
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
KR20190039937A (ko) 2016-07-08 2019-04-16 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
WO2018013855A2 (en) 2016-07-14 2018-01-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Il-15/il-15 receptor alpha treatment regimens and use with therapeutic vaccines
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
ES2963226T3 (es) 2016-12-07 2024-03-26 Agenus Inc Anticuerpos ANTI-CTLA-4 y métodos de uso de los mismos
EP3559039A1 (de) 2016-12-22 2019-10-30 Università Degli Studi Magna Graecia Catanzaro Gegen ein eindeutiges sialoglycosyliertes krebsassoziiertes epitop von cd43 gerichteter monoklonaler antikörper
CN110198954A (zh) 2017-01-13 2019-09-03 艾吉纳斯公司 与ny-eso-1结合的t细胞受体和其使用方法
RU2019122408A (ru) 2017-01-20 2021-02-20 Новартис Аг Средство комбинированной терапии для лечения рака
WO2018134784A1 (en) 2017-01-20 2018-07-26 Novartis Ag Combination therapy for the treatment of cancer
JP7307681B2 (ja) 2017-02-17 2023-07-12 カムリス インターナショナル インコーポレイテッド 汎用性抗毒素
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
JP7297672B2 (ja) 2017-04-13 2023-06-26 アジェナス インコーポレイテッド 抗ｃｄ１３７抗体およびその使用方法
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
MA50957A (fr) 2017-05-01 2020-10-14 Agenus Inc Anticorps anti-tigit et leurs méthodes d'utilisation
WO2018229706A1 (en) 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer
TWI728250B (zh) 2017-06-21 2021-05-21 美商基利科學股份有限公司 靶向hiv gp120及cd3之多特異性抗體
JP7437301B2 (ja) 2017-08-25 2024-02-22 ファイヴ プライム セラピューティクス インク Ｂ７－ｈ４抗体及びその使用方法
CN111278854A (zh) 2017-09-04 2020-06-12 艾吉纳斯公司 与混合谱系白血病(mll)特异性磷酸肽结合的t细胞受体和其使用方法
JP7039694B2 (ja) 2017-10-31 2022-03-22 スターテン・バイオテクノロジー・ベー・フェー 抗ａｐｏｃ３抗体およびその使用方法
EP3746104A1 (de) 2018-02-02 2020-12-09 Novartis AG Kombination von sting-agonist und il-15/il15-ra zur behandlung von krebs
CN111741978A (zh) 2018-02-21 2020-10-02 戊瑞治疗有限公司 B7-h4抗体制剂
WO2019165075A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody dosing regimens
EP3759142A1 (de) 2018-03-02 2021-01-06 Five Prime Therapeutics, Inc. B7-h4-antikörper und verfahren zur verwendung davon
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
WO2020003172A1 (en) 2018-06-26 2020-01-02 Mor Research Applications Transthyretin antibodies and uses thereof
CN112368052A (zh) 2018-07-03 2021-02-12 吉利德科学公司 靶向hiv gp120的抗体和使用方法
WO2020070678A2 (en) 2018-10-03 2020-04-09 Staten Biotechnology B.V. Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
CA3114955A1 (en) 2018-10-15 2020-04-23 Five Prime Therapeutics, Inc. Combination therapy for cancer
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
WO2021011544A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
CN114585644A (zh) 2019-08-30 2022-06-03 艾吉纳斯公司 抗cd96抗体及其使用方法
JP7398556B2 (ja) 2019-09-30 2023-12-14 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖワクチン及びｈｂｖを治療する方法
CN116322757A (zh) 2019-11-14 2023-06-23 埃利克斯疗法公司 用于疫苗的剂量方案
IL295278A (en) 2020-02-05 2022-10-01 Novartis Ag cho cell expressing heterodimers of il-15
CA3166155A1 (en) 2020-02-18 2021-08-26 Spencer LIANG Pilra antibodies and methods of use thereof
KR20220151195A (ko) 2020-03-06 2022-11-14 오엔에이 테라퓨틱스 에스.엘. 항-cd36 항체 및 암을 치료하기 위한 이의 용도
MX2022013352A (es) 2020-04-22 2022-11-30 Novartis Ag Composiciones farmaceuticas y productos farmaceuticos de interleucina-15 humana heterodimerica (hetil-15).
EP4153312A1 (de) 2020-05-17 2023-03-29 AstraZeneca UK Limited Sars-cov-2-antikörper und verfahren zur auswahl und verwendung davon
KR20230038783A (ko) 2020-07-20 2023-03-21 아스트라제네카 유케이 리미티드 Sars-cov-2 단백질, 항-sars-cov-2 항체, 및 이를 사용하는 방법
AU2021325954A1 (en) 2020-08-14 2023-03-02 The Trustees Of The University Of Pennsylvania Novel AAV capsids and compositions containing same
US11725052B2 (en) 2020-08-18 2023-08-15 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof
AU2021333577A1 (en) 2020-08-25 2023-03-30 Gilead Sciences, Inc. Multi-specific antigen binding molecules targeting HIV and methods of use
EP4228610A1 (de) 2020-10-13 2023-08-23 Kriya Therapeutics, Inc. Virale vektorkonstrukte zur abgabe von cytokin-codierenden nukleinsäuren und verwendungen davon zur behandlung von krebs
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
JP2023550581A (ja) 2020-10-29 2023-12-04 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ａａｖカプシド及びそれを含有する組成物
WO2022125927A1 (en) 2020-12-11 2022-06-16 The University Of North Carolina At Chapel Hill Compositions and methods comprising sfrp2 antagonists
KR20230131481A (ko) 2021-01-14 2023-09-13 길리애드 사이언시즈, 인코포레이티드 Hiv 백신 및 이의 사용 방법
CA3206107A1 (en) 2021-01-26 2022-08-04 Brian Furmanski Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same
CA3208612A1 (en) 2021-02-19 2022-08-25 Beam Therapeutics Inc. Recombinant rabies viruses for gene therapy
AR125467A1 (es) 2021-04-27 2023-07-19 Univ Pennsylvania Cápsides de virus adenoasociados derivados de porcinos y usos de los estos
IL308404A (en) 2021-04-27 2024-01-01 Generation Bio Co Non-viral DNA vectors expressing therapeutic antibodies and uses thereof
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
CA3218481A1 (en) 2021-06-14 2022-12-22 argenx BV Anti-il-9 antibodies and methods of use thereof
US20230038295A1 (en) 2021-06-25 2023-02-09 Homology Medicines, Inc. Adeno-associated virus packaging systems
IL309934A (en) 2021-07-30 2024-03-01 Ona Therapeutics S L Anti-CD36 antibodies and their use for cancer treatment
CA3230629A1 (en) 2021-09-08 2023-03-16 Beam Therapeutics Inc. Viral guide rna delivery
WO2023064955A1 (en) 2021-10-15 2023-04-20 Cytomx Therapeutics, Inc. Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
US20230183382A1 (en) 2021-10-15 2023-06-15 Cytomx Therapeutics, Inc. Activatable polypeptide complex
AU2022367525A1 (en) 2021-10-15 2024-05-02 Amgen Inc. Activatable polypeptide complex
CA3234162A1 (en) 2021-10-15 2023-04-20 Michele Fiscella Antibodies and methods of using thereof
WO2023114901A2 (en) 2021-12-15 2023-06-22 Oxford Biomedica Solutions Llc Methods and compositions for the production of adeno-associated virus
WO2023133561A1 (en) 2022-01-09 2023-07-13 Kriya Therapeutics, Inc. Vector constructs for delivery of nucleic acids encoding therapeutic anti-igf-1r antibodies and methods of using the same
WO2023154678A1 (en) 2022-02-08 2023-08-17 Amgen Inc. Codon-optimized nucleic acids encoding ocrelizumab
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
WO2023194796A2 (en) 2022-04-04 2023-10-12 Vectory B.V. Recombinant aav capsid proteins
WO2023209177A1 (en) 2022-04-29 2023-11-02 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
WO2023242633A2 (en) 2022-06-14 2023-12-21 Vectory B.V. Recombinant aav capsid proteins
WO2023242361A1 (en) 2022-06-15 2023-12-21 argenx BV Fcrn binding molecules and methods of use
WO2023248008A2 (en) 2022-06-20 2023-12-28 Vectory B.V. Degron fusion constructs
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024015966A2 (en) 2022-07-15 2024-01-18 The Trustees Of The University Of Pennsylvania Recombinant aav having aav clade d and clade e capsids and compositions containing same
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2024040132A2 (en) 2022-08-16 2024-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Synergistic interactions for improved cancer treatment
WO2024054993A1 (en) 2022-09-09 2024-03-14 Kriya Therapeutics, Inc. Vector constructs for delivery of nucleic acids encoding therapeutic anti-ctla4 antibodies and methods of using the same
WO2024105445A2 (en) 2022-11-14 2024-05-23 argenx BV Fcrn antagonist molecules and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US33653A (en) * 1861-11-05 Improvement in swivel hooks and rings
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4959455A (en) * 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
IL89567A0 (en) 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US5082767A (en) * 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
EP0465529B1 (de) * 1989-03-21 1998-04-29 Vical, Inc. Expression von exogenen polynukleotidsequenzen in wirbeltieren
US4970491A (en) 1989-04-03 1990-11-13 Trams Enterprises, Inc. Air pressure alert system
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US6174666B1 (en) * 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA

Also Published As

Publication number Publication date
EP0635062B1 (de) 1999-12-29
JP2007209345A (ja) 2007-08-23
US20020192660A1 (en) 2002-12-19
US5972596A (en) 1999-10-26
US6291664B1 (en) 2001-09-18
US5965726A (en) 1999-10-12
CA2132208C (en) 1999-09-14
JP2009165497A (ja) 2009-07-30
US6174666B1 (en) 2001-01-16
US6414132B1 (en) 2002-07-02
JP2010252809A (ja) 2010-11-11
AU3969493A (en) 1993-11-08
JP4180650B2 (ja) 2008-11-12
WO1993020212A1 (en) 1993-10-14
US6794498B2 (en) 2004-09-21
DE69327456D1 (de) 2000-02-03
JPH07509121A (ja) 1995-10-12
AU678157B2 (en) 1997-05-22
CA2132208A1 (en) 1993-10-14
EP0635062A1 (de) 1995-01-25
JP4336371B2 (ja) 2009-09-30

Similar Documents

Publication Publication Date Title
DE69327456T2 (de) VERFAHREN ZUR ELIMINIERUNG VON INHIBIERENDEN/DESTABILISIERENDEN REGIONEN VON mRNA
DE69329461D1 (de) Verfahren zur extraktion und reinigung von hamoglobin
DE69316205D1 (de) Verfahren und reagens zur spaltung und entschützen von oligonukleotide
DE69313249T2 (de) Verfahren zur beschränkten Koaleszenz
DE69636451D1 (de) Verfahren zur korrosionsinhibierung unter verwendung von n-halo-azolen
DE59209786D1 (de) Verfahren zur Schutzbeschichtung von Substraten sowie Beschichtungsanlage
DE59305971D1 (de) Verfahren zur entölung von rohlecithin
DE69316385D1 (de) Verfahren zur reinigung von acetanhydrid
ATE176399T1 (de) Verfahren zur inaktivierung von spermien
DE69605902T2 (de) Verfahren zur stabilisierung von schlamm
DE69325382D1 (de) Verfahren zur oberflächenmodifikation
DE69526796T2 (de) Verfahren zur inhibierung von pflanzenkrankheiten
ATE204120T1 (de) Verfahren zur vermehrung von pflanzenmaterial
DE69405594D1 (de) Verfahren zur Inhibierung der Endotoxin-Aktivität
DE69533774D1 (de) Verfahren und system zur verteilten kontrolle von hardware
DE69700801D1 (de) Verfahren zur Kopositionierung von Satelliten
DE69314365T2 (de) Verfahren zur Monohydroxylierung von Phenolverbindungen
DE69328969D1 (de) Verfahren zur stereospezifischen hydrolyse von piperidin-dion derivaten
DE69514535D1 (de) Verfahren zur raffinierung von methylal
DE69321488D1 (de) Verfahren zur extraktion und reinigung von alkaloiden
DE59509345D1 (de) Verfahren zur sprachsteuerung von anlagen und geräten
DE69409640D1 (de) Verfahren zur selektiven hydrogenation von dinitrilen
DE69604616D1 (de) Verfahren zur Polymerisierungshemmung
DE69516038D1 (de) Verfahren zur Restaurierung von Kunstwerken
DE59604907D1 (de) Verfahren zur reduktion von nitroverbindungen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: THE NATIONAL INSTITUTES OF HEALTH, ROCKVILLE, MD.,

8364 No opposition during term of opposition